Cannabinoid derivatives

US12325709B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12325709-B2
Application numberUS-202017765856-A
CountryUS
Kind codeB2
Filing dateOct 2, 2020
Priority dateOct 2, 2019
Publication dateJun 10, 2025
Grant dateJun 10, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

First claim

Opening claim text (preview).

We claim: 1. A compound having structural formula: or an enantiomer, diastereomer, racemate, or tautomer thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, or tautomer, wherein the  moiety is R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —OR 1a , —(C 1 -C 4 alkyl)OR 1a , —SR 1a , —(C 1 -C 4 alkyl)SR 1a , —NR 1b R 1c , —(C 1 -C 4 alkyl)NR 1b R 1c , —(C 1 -C 4 alkyl)C(O)NR 1b R 1c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo when attached to a ring of appropriate saturation, wherein R 1a , R 1b , and R 1c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl; R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —OR 2a , —(C 1 -C 4 alkyl)OR 2a , —SR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo when attached to a ring of appropriate saturation, wherein R 2a , R 2b , and R 2c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl; R 3 is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 O(C 1 -C 8 alkyl), —(C 0 -C 4 alkyl)-NR 3a R 3b , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein R 3a and R 3b are each independently hydrogen or C 1 -C 6 alkyl; R 4 is hydrogen,  wherein Q 1 is O or S; R 4a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 , C 2 or C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 4c R 4d ), (—C 1 , C 2 or C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl, R 4b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 , C 2 or C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 4c R 4d ), —(C 1 , C 2 or C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl, wherein R 4c and R 4d are hydrogen or C 1 -C 6 alkyl, or R 4a and R 4b together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring, R 4c is hydrogen, C 1 -C 8 alkyl, cycloalkyl or aryl, R 4f is —OR 4g , C 1 -C 8 alkyl, cycloalkyl or NR 4h R 4i , wherein R 49 is C 1 -C 8 alkyl, cycloalkyl, or aryl, and wherein R 4h and R 4i are C 1 -C 8 alkyl, or R 4h and R 4i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and R 4j and R 4k are each independently hydrogen or C 1 -C 8 alkyl; R 5 is hydrogen, C 1 -C 8 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl); R 6 is —OR 6a , wherein R 6a is hydrogen, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl); and R 7 is hydrogen,  provided R 7 is not hydrogen when R 4 is hydrogen, wherein Q 2 is O or S; R 7a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 7c R 7d ), —(C 1 , C 2 or C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl, R 7b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 7c R 7d ), —(C 1 , C 2 or C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl, wherein R 70 and R 7d are hydrogen or C 1 -C 6 alkyl, or R 7a and R 7h together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring, R 7e is H, C 1 -C 8 alkyl, cycloalkyl, or aryl, R 7f is —OR 7g , C 1 -C 8 alkyl, cycloalkyl, or NR 7h R 7i , wherein R 7g is C 1 -C 8 alkyl, cycloalkyl, or aryl, and wherein R 7h and R 7i are C 1 -C 8 alkyl, or R 7h and R 7i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and R 7j and R 7k are each independently hydrogen or C 1 -C 8 alkyl; wherein each alkyl, alkenyl and alkynyl is unsubstituted, halogenated, substituted with one hydroxyl group, one or two C 1 -C 6 alkoxy groups, one or two —C(O)O(C 1 -C 4 alkyl) groups, or one or two oxo groups; each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each fused ring having 3-8 ring members, and is substituted with 0-6 R 8 ; each heterocycloalkyl has 3-10 ring members and 1-3 heteroatoms where each is independently nitrogen, oxygen or sulfur and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each having 3-8 ring members, and is substituted with 0-6 R 8 ; each aryl is a phenyl or a naphthyl, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 ; each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms, where each is independently nitrogen, oxygen or sulfur or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms where each is independently nitrogen, oxygen or sulfur, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 , in which each R 8 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —(C 0 -C 3 alkyl)-OR B , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2

Assignees

Inventors

Classifications

  • Sulfur atoms · CPC title

  • from aromatic carboxylic acids · CPC title

  • 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles · CPC title

  • with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

  • Nitrogen atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12325709B2 cover?
This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.
Who is the assignee on this patent?
Canopy Growth Corp
What technology area does this patent fall under?
Primary CPC classification C07D205/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).